Hussman Strategic Advisors Inc. Purchases New Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Hussman Strategic Advisors Inc. bought a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 31,500 shares of the company's stock, valued at approximately $913,000. Hussman Strategic Advisors Inc. owned about 0.07% of Amphastar Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Signaturefd LLC increased its stake in shares of Amphastar Pharmaceuticals by 147.7% during the first quarter. Signaturefd LLC now owns 872 shares of the company's stock worth $25,000 after purchasing an additional 520 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $38,000. GAMMA Investing LLC lifted its holdings in Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after buying an additional 424 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after buying an additional 348 shares in the last quarter. Finally, Huntington National Bank lifted its holdings in Amphastar Pharmaceuticals by 36.9% during the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock worth $50,000 after buying an additional 361 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMPH has been the topic of a number of recent analyst reports. Piper Sandler dropped their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Wells Fargo & Company lowered their price objective on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and set a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $32.33.

Amphastar Pharmaceuticals Trading Down 5.0%

Shares of NASDAQ:AMPH traded down $1.08 during trading on Friday, reaching $20.62. The stock had a trading volume of 430,242 shares, compared to its average volume of 500,236. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $20.43 and a fifty-two week high of $53.96. The business has a fifty day moving average price of $24.23 and a 200-day moving average price of $27.72. The stock has a market cap of $972.03 million, a P/E ratio of 7.47, a PEG ratio of 5.37 and a beta of 0.72. The company has a quick ratio of 2.02, a current ratio of 2.95 and a debt-to-equity ratio of 0.80.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.